HIV & PrEP Commercial Acceleration: Gilead Sciences Outperforms Q2 2026 Revenue Estimates at $7.8 Billion, Offsetting One-Time M&A Charges

Key Development

American biopharmaceutical major Gilead Sciences, Inc. (NASDAQ: GILD) officially released its Q2 2026 financial readouts, generating total quarterly revenues of $7.8 billion (a 10% YoY increase), outperforming Wall Street consensus estimates of $7.4 billion. Top-line expansion was driven by double-digit growth across its HIV treatment and PrEP franchise (+12%), alongside contributions from oncology asset Trodelvy® and liver disease therapy Livdelzi®.

Q2 2026 Financial Highlights & Core Metrics:

• Earnings & Acquisition-Related Charges: Gilead reported a non-GAAP adjusted diluted loss of $6.75 per share (beating consensus loss estimates of $7.24). The GAAP net loss was driven by a $9.08 per share charge in acquired in-process research and development (IPR&D) expenses linked to the strategic acquisitions of Arcellx (cell therapy), Ouro Medicines (autoimmune), and Tubulis (ADCs).

• Full-Year 2026 Guidance Upgrade: Gilead raised its full-year total product sales guidance to $30.1 billion – $30.4 billion (up from $30.0B – $30.4B). Expected full-year HIV sales growth was upgraded to 9% – 10% (up from 8% previously).

• Adjusted EPS Outlook Improvement: Full-year 2026 adjusted loss per share expectations were narrowed to $0.30 – $0.65 (improving from the previous range of $0.65 – $1.65 loss).

Why It Matters

• Commercial Dominance Across PrEP Franchises (Yeztugo® & Descovy®):

  • Yeztugo® (lenacapavir): The bi-annual injectable PrEP therapy generated $232 million in Q2 sales (beating consensus estimates of $210 million). Gilead reaffirmed confidence that Yeztugo will achieve $1.0 billion in full-year 2026 sales.

  • Descovy®: Q2 revenues surged 48% to $967 million. Combined quarterly PrEP sales (Yeztugo + Descovy) surpassed $1.0 billion for the first time, putting the PrEP business on a $4.0 billion annual run-rate in 2026.

• Biktarvy® Reaffirms Anchor Position: Flagship HIV therapy Biktarvy® recorded $3.8 billion in quarterly sales (+7% YoY, beating estimates of $3.63 billion), capturing over 52% of the U.S. HIV treatment market.

• Oncology & Liver Disease Expansion: Trop-2 ADC Trodelvy® grew 26% to $457 million (supported by a June 2026 FDA approval in first-line mTNBC). The liver disease portfolio expanded 10% to $877 million, boosted by uptake for primary biliary cholangitis (PBC) therapy Livdelzi®.

• Favorable Legal Ruling: The California Supreme Court ordered the dismissal of a long-standing negligence lawsuit alleging Gilead delayed the development of safer tenofovir-based HIV drugs two decades ago, resolving a historical legal liability.

Healthcare Insight Analysis

From the perspective of Healthcare Insight, Gilead Sciences’ Q2 2026 financial readouts illustrate a strategy combining PrEP Market Monopolization with R&D Pipeline Re-investment.

While traditional HIV treatment market expansion experienced slight headwinds due to shifts in uninsured patient volumes following the expiration of pandemic-era ACA subsidies, CEO Daniel O’Day mitigated these dynamics by expanding the Pre-Exposure Prophylaxis (PrEP) market:

1. Differentiating via Bi-Annual Administration: Yeztugo’s twice-yearly dosing schedule—achieving a $>70\%$ 12-month persistency rate—is capturing market share from daily oral options, establishing lenacapavir as a standard of care in global HIV prevention.

2. Deploying PrEP Cash Flow to Fund M&A Strategy: Generating $3.6 billion in quarterly operating cash flow enabled Gilead to absorb one-time IPR&D charges associated with acquiring Arcellx, Ouro, and Tubulis. This M&A strategy diversifies Gilead’s oncology and immunology pipeline ahead of Biktarvy’s late-2030s loss of exclusivity.

Market Implications

1. Positive Re-Rating for GILD Equity: Beating quarterly revenue estimates while raising full-year top-line guidance provides support for Gilead Sciences shares on the Nasdaq.

2. Elevating Competition in Long-Acting Injectables: Yeztugo’s commercial launch momentum will likely prompt competitors (such as ViiV Healthcare / GSK) to accelerate Phase III development for ultra-long-acting PrEP candidates.

3. Expanding Trodelvy® Market Share in First-Line Oncology: FDA label expansion into first-line mTNBC positions Trodelvy as a direct competitor to Enhertu® (AstraZeneca / Daiichi Sankyo) across global cancer centers.

Performance Ledger: Gilead Sciences Q2 2026 Operational Metrics

Source: https://www.reuters.com/legal/litigation/gilead-second-quarter-sales-rise-8-beating-wall-street-estimates-2026-08-04/